Latest Filings

Issuer Activity

Overview :: CVS Caremark Corporation (N:CVS) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent stock price and fundamental snapshot currently not available for CVS Caremark Corporation (N:CVS)
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 3:42pm ET July 31st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -22,107  
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -22,107 $76.77
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 22,107 $30.16
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -48,178  
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -26,811  
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock S - Open market or private sale -74,989 $75.88
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 48,178 $28.10
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 26,811 $41.17
May 9/14 May 8/14 Weldon William C Direct Ownership Share Credits A - Grant, award or other under Rule 16b-3(d) 1,846 $75.86
May 9/14 May 8/14 Swift Richard J Direct Ownership Share Credits A - Grant, award or other under Rule 16b-3(d) 1,508 $75.86
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 3:42pm ET July 31st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -22,107  
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock S - Open market or private sale -22,107 $76.77
Jul 22/14 Jul 21/14 Boratto Eva C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 22,107 $30.16
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -48,178  
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -26,811  
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock S - Open market or private sale -74,989 $75.88
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 48,178 $28.10
Jul 3/14 Jul 1/14 Denton David M Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 26,811 $41.17
May 9/14 May 8/14 Weldon William C Direct Ownership Share Credits A - Grant, award or other under Rule 16b-3(d) 1,846 $75.86
May 9/14 May 8/14 Swift Richard J Direct Ownership Share Credits A - Grant, award or other under Rule 16b-3(d) 1,508 $75.86
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
David W. Dorman
Independent Chairman of the Board
Jonathan C. Roberts
Executive Vice President; President of CVS Caremark Pharmacy Services
Larry J. Merlo
President, Chief Executive Officer, Director
David M. Denton
Chief Financial Officer, Executive Vice President
Lisa G. Bisaccia
Chief Human Resource Officer, Senior Vice President
Thomas M. Moriarty
Executive Vice President, General Counsel
Troyen A. Brennan
Executive Vice President, Chief Medical Officer
Helena B. Foulkes
Executive Vice President, President of CVS/pharmacy
J. David Joyner
Executive Vice President
Per G. H. Lofberg
Executive Vice President
   
Company Contact
Address: One CVS Drive
WOONSOCKET RI 02895
Tel: 1-800-2010938
Website: info.cvscaremark.com
IR: phx.corporate-ir.net/phoenix.zhtml?c=99533&p=irol-irhome
Business Overview
CVS Caremark Corporation (CVS Caremark), together with its subsidiaries, is a pharmacy health care provider in the United States. CVS Caremark provides pharmacy services through its pharmacy benefit management (PBM), mail order and specialty pharmacy division, CVS Caremark Pharmacy Services; approximately 7,300 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and its online retail pharmacy, CVS.com. The Company operates in three business segments: Pharmacy Services, Retail Pharmacy and Corporate. Its corporate segment provides management and administrative services. The Corporate segment consists of certain aspects of its executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. In January 2014, Cvs Caremark Corporation completed the acquisition of Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc.
Financial Overview
For the three months ended 31 March 2014, CVS Caremark Corporation revenues increased 6% to $32.69B. Net income increased 18% to $1.13B. Revenues reflect Pharmacy Services Segment increase of 10% to $20.2B, Retail Pharmacy Segment increase of 3% to $16.48B, Comp. Store Sales (Growth - %) - Pharmay increase from -2.3 to 3.8%, Retail Sales-Retail Pharmacy increase of 3% to $16.48B.
Employees: 130,000 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $101,458M as of Mar 31, 2014
Annual revenue (TTM): $128,699M as of Mar 31, 2014
EBITDA (TTM): $10,212M as of Mar 31, 2014
Net annual income (TTM): $4,775M as of Mar 31, 2014
Free cash flow (TTM): $3,116M as of Mar 31, 2014
Net Debt Last Fiscal Year: $10,562M as of Mar 31, 2014
Shares outstanding: 1,169,230,063 as of Apr 25, 2014
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Express Scripts Holding C (OQ:ESRX)
Cardinal Health (N:CAH)
McKesson (N:MCK)